Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com
Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Patients with HER2-positive breast cancer showed benefit with T-DM1 treatment. | Image Credit- Marina - stock.adobe.com
June 27th 2024

T-DM1 Shows Promise With Low Recurrence Rates in HER2-Positive Breast Cancer

Cameron Santoro
Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score potentially identifying those at higher risk of recurrence.
Breast cancer ribbon. | Image Credit: Visual Generation - stock.adobe.com
June 25th 2024

Breast Cancer Risk Reduced by Bariatric Surgery in Patients With High Insulin Levels

Cameron Santoro
A Swedish study suggests bariatric surgery may lower breast cancer risk in obese women, particularly those with high insulin levels at baseline.
Group of people holding bc ribbon | Image Credit/ Rawpixel.com - stock.adobe.com
June 20th 2024

Breast Cancer Risk Management in Transgender Men After Chest Contouring Surgery

Cameron Santoro
This study highlights the lack of clear guidelines for breast cancer management in transgender men after chest contouring surgery. While data is limited, the authors suggest adapting existing recommendations for cisgender women and implementing risk management strategies like pre-surgery evaluation and education.
Black woman doctor | Image Credit | mihail - stock.adobe.com
June 14th 2024

Neighborhood Deprivation Linked to Increased Breast Cancer Deaths for White Women, but Not Black Women

Cameron Santoro
A recent study found that neighborhood deprivation is associated with higher breast cancer death rates for non-Hispanic White women, but not Black women. This suggests factors beyond socioeconomic status contribute to the racial disparity.
Medical technology and digital health network concept | Image Credit: © ipopba - stock.adobe.com
June 13th 2024

Reducing Delays in Breast Cancer Care Using an Innovative Digital Health Platform

Dennis R. Holmes, MD Steven D. Evans, MD Warren Fisher, DO Darren Wheeler, MD Riya Pulicharam, MD, CPI
The use of a novel digital health platform achieved a 55% reduction in time to treatment among women with a new diagnosis of breast cancer.
Breast cancer research | Image Credit: vectorfusionart - stock.adobe.com
June 11th 2024

Trastuzumab Deruxtecan Effective For HR-Positive, HER2-Low Breast Cancer Treatment After Endocrine Therapy

Cameron Santoro
Findings from ASCO 2024 suggest deruxtecan (T-DXd) may become a preferred first-line treatment for patients with hormone receptor (HR)-positive, HER2-low metastatic breast cancer that progressed after endocrine therapy.
Woman exercising with dumbbells | Image Credit: SEVENNINE_79 - stock.adobe.com
June 5th 2024

Exercise After Breast Cancer Surgery Improves Shoulder Function, Quality of Life

Cameron Santoro
Patients with breast cancer who participate in a tailored exercise program after surgery have better shoulder function after 1 month compared with those who received usual care.
Blood sample for BRCA test | Image Credit: jarun011 - stock.adobe.com
May 31st 2024

Multigene Testing Offers Cost-Effectiveness, Broader Approach to Breast Cancer Prevention

Cameron Santoro
A large US study showed population-based multigene testing might be a cost-effective way to identify women at risk for breast and ovarian cancer, potentially preventing more cases but raising concerns about generalizability and cost.
Woman receiving mammogram | Image Credit: Prathankarnpap - stock.adobe.com
May 29th 2024

Patient Characteristics Affect AI Performance in Breast Cancer Screening

Cameron Santoro
A US study found that a commercially available artificial intelligence (AI) algorithm for breast cancer screening produced more false-positives in Black patients and people with denser breasts, highlighting the importance of diverse datasets in training AI algorithms to reduce health care disparities.
Stephanie L. Graff, MD, an expert on breast cancer
May 17th 2024

Research Landscape: Endocrine Therapies for ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD
Stephanie Graff, MD, concludes the discussion with thoughts on endocrine therapies in development for patients with ER+/HER2- metastatic breast cancer.
Illustration of diverse women with breast cancer, obesity | Image Credit: Rawpixel.com - stock.adobe.com
May 13th 2024

Metabolic Syndrome, Obesity Contribute to Breast Cancer Mortality in Postmenopausal Women

Cameron Santoro
A large study finds that obesity and metabolic syndrome raise breast cancer mortality risk, but through different mechanisms. Metabolic syndrome is linked to a specific type of breast cancer, whereas obesity increases risk across all breast cancer subtypes.
Patient undergoing chemotherapy | Image Credit: agny_illustration - stock.adobe.com
May 9th 2024

Breast Cancer Treatment Disparities Impact Survival Based on Race, Age, Socioeconomics

Cameron Santoro
A new study has linked racial and ethnic disparities with factors like age, income, and insurance to breast cancer treatment decline. Patients who received all treatments had better survival, highlighting the need for interventions to improve access and reduce disparities.
Breast cancer costs. | Image Credit: Cozine - stock.adobe.com
May 6th 2024

Social Equity, Strong Health Care Systems Can Improve Advanced Breast Cancer Outcomes Globally

Cameron Santoro
Disparities in health care systems around the world limit access to effective treatments for advanced breast cancer, especially for people in low- and middle-income countries and marginalized communities. Stronger health systems and social education efforts are necessary to improve outcomes for all patients.
Stephanie L. Graff, MD, an expert on breast cancer
May 3rd 2024

Best Practices for ESR1 Mutation Testing in Patients With Breast Cancer

Stephanie L. Graff, MD
An expert on breast cancer reviews currently available tests for ESR1 mutations and provides clinical insights on best practices for testing.
Stephanie L. Graff, MD, an expert on breast cancer
May 3rd 2024

Overview of ESR1 Mutations in ER+/HER2- Metastatic Breast Cancer

Stephanie L. Graff, MD
Stephanie L. Graff, MD, provides an overview of ESR1 mutations in ER+/HER2- metastatic breast cancer, highlighting their prevalence, clinical implications, and challenges.
3D rendered graphic of breast cancer | Image Credit: Sebastian Kaulitzki - stock.adobe.com
May 1st 2024

Destiny-Breast06 Results Offer New Hope for Patients With HR-Positive, HER2-Low Metastatic Breast Cancer

Cameron Santoro
Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low metastatic breast cancer who had prior endocrine therapy.
Physician and Patient at Mammography Exam. |Image Credit: LStockStudio - stock.adobe.com
April 30th 2024

USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit

Cameron Santoro
The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
FDA approval. | Image Credit: monticellllo - stock.adobe.com
April 29th 2024

FDA Approves Hercessi, the Sixth Trastuzumab Biosimilar

Cameron Santoro
The recent FDA approval of Hercessi expands access to a treatment previously burdened by high costs. Hercessi joins the 5 other biosimilars already on the market.
Young woman with cancer-related fatigue | Image Credit: Solid photos - stock.adobe.com
April 24th 2024

Melatonin Fails to Ease Fatigue in Patients With Early-Stage Breast Cancer Undergoing Radiotherapy

Cameron Santoro
Melatonin showed no benefit for cancer-related fatigue or other symptoms in women with early-stage breast cancer receiving radiotherapy treatment.
Breast Cancer, Macro-Mediterranean diet| Image Credit: r2 studio - stock.adobe.com
April 12th 2024

Breast Cancer Recurrence: High Adherence to Macro-Mediterranean Diet Hints Benefit

Cameron Santoro
Macro-Mediterranean diets for patients with high-risk breast cancer recurrence found no overall reduction, but women who adhered more closely to the diet showed potential benefit.
Young women with breast cancer | Image Credit: georgerudy - stock.adobe.com
April 11th 2024

Young Breast Cancer Survivors Without Germline Mutation Show Lower Risk of Second Cancer

Cameron Santoro
Young breast cancer survivors without a specific genetic mutation have a lower risk of developing second primary breast cancer within 10 years of diagnosis.
Mammogram breast screening | Image Credit: Dmitry Kovalchuk - stock.adobe.com
April 9th 2024

Mammography Use Linked to Social Determinants, Revealing Need to Bridge Gaps With Community Support

Cameron Santoro
While mammograms are crucial for early detection of breast cancer and can save lives, social determinants of health and health-related social needs create barriers to access, especially for those with financial hardship, lack of transportation, or social isolation.
Patient consulting with physician. | Image Credit: Chinnapong - stock.adobe.com
April 6th 2024

Breast Cancer Risk Not Linked to SSRIs; Prolactin Levels Warrant Careful Prescribing

Cameron Santoro
A recent study found a minor link between prolactin levels and the risk of developing estrogen receptor (ER)-positive or ER-negative breast cancers. However, there was no association found between the use of selective serotonin reuptake inhibitors (SSRIs) and breast cancer risk.
Woman hands with breast cancer ribbon. | Image Credit: Konstantin Yuganov - stock.adobe.com
April 1st 2024

Supporting Breast Cancer Survivors Through Psychosocial Challenges

Cameron Santoro
Breast cancer survivors face a complex landscape of challenges including lingering symptoms, anxieties about the future, identity shifts, and potential social isolation. However, the study identifies personal growth fostered by the experience, further underscoring the critical role of social support and open communication with health care providers in navigating this journey.
Cryoprobe. | Image Credit: Alexander Kurilchik - stock.adobe.com
March 31st 2024

Cryoablation Exhibits Advantages as Minimally Invasive Option for Early Breast Cancer

Cameron Santoro
While offering advantages like faster recovery and high patient satisfaction, cryoablation for the treatment of early-stage breast cancer is still under investigation for effectiveness and requires further research for wider adoption.
Older adult patient receiving mammogram | Image Credit: Peakstock - stock.adobe.com
March 20th 2024

Tailoring Treatment, Personalized Care for Older Adult Patients With Advanced Breast Cancer

Cameron Santoro
Older adults with advanced breast cancer need personalized treatment plans considering fitness, preferences, and potential limitations for optimal outcomes and quality of life.
Molecular mapping on a computer | Image Credit: JR-50 - stock.adobe.com.jpeg
March 14th 2024

Night Light Pollution Linked to Breast Cancer, Particularly for Asian Populations, ER+ Cases

Cameron Santoro
A large-scale study suggests increased light at night exposure is linked to a higher risk of breast cancer, particularly in Asian populations and women with estrogen receptor-positive tumors (ER+).
Patient receives injection of ozone therapy | Image Credit: HENADZY - stock.adobe.com
March 11th 2024

Ozone Therapy May Kill Breast Cancer Cells, Reduce Adverse Effects For Patients

Cameron Santoro
Early research suggests ozone therapy may fight breast cancer cells and lessen adverse effects for patients undergoing treatment, but more research is necessary.
Woman undergoing cancer therapy wearing surgical mask | Image Credit: Pixel-Shot - stock.adobe.com
March 6th 2024

Stable Treatment Remained in Early Breast Cancer Diagnosis During Pandemic

Cameron Santoro
A study of patients diagnosed with early breast cancer during the COVID-19 pandemic found that the public health crisis did not produce significant changes in or delays treatment, despite many women presenting with palpable tumors.
Link between genetics and breast cancer | Image Credit: David Carillet - stock.adobe.com
February 29th 2024

Multigene Assays Advance Genetic Testing in Breast Cancer, Drive Personalized Medicine

Cameron Santoro
Multigene assays allow for patients to receive personalized breast cancer treatment by identifying promising therapeutic targets, which could improve patient clinical outcomes in the long term and help providers better understand tumor biology.
<12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo